PMCB (PharmaCyte Biotech) EBITDA Margin %: 0.00% (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech EBITDA Margin %?

PharmaCyte Biotech PMCB -0.30% 32 EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, PharmaCyte Biotech ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PharmaCyte Biotech's EBITDA for the three months ended in Jan. 2026 was $-2.12 Mil. PharmaCyte Biotech's Revenue for the three months ended in Jan. 2026 was $0.00 Mil. Therefore, PharmaCyte Biotech's EBITDA margin for the quarter that ended in Jan. 2026 was 0.00%.

PharmaCyte Biotech  (NAS:PMCB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

PharmaCyte Biotech EBITDA Margin % Related Terms

PharmaCyte Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech EBITDA Margin % Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PMCB vs IMNN, ACXP, ENVB: EBITDA Margin % Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's EBITDA Margin % falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PharmaCyte Biotech's EBITDA Margin % for the fiscal year that ended in Apr. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Apr. 2025 )/Revenue (A: Apr. 2025 )
=-4.378/0
= %

PharmaCyte Biotech's EBITDA Margin % for the quarter that ended in Jan. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-2.118/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
PharmaCyte Biotech (PMCB) has a EBITDA Margin % of 0.00% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #999999 out of 945 companies in the Biotechnology industry.
Is PharmaCyte Biotech's EBITDA Margin % too high?
PharmaCyte Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, PharmaCyte Biotech ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's EBITDA Margin % compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #999999 out of 945 companies for EBITDA Margin %. This places PharmaCyte Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price